AMENDMENTS TO THE SPECIFICATION

Please amend Table 8 on page 41 of the specification to include sequence identification numbers, as follows.

Table 8. Tat-derived 15-mer peptides

Peptide	Aminoacid position	Amino acid sequence[a]	SEQ ID NO:
TC27	1-15	MEPVDPRLEPWKHPG	33
TC28	6-20	PRLEPWKHPGSQPKT	34
TC29	11-25	WKHPGSQPKTACTNC	35
TC30	16-30	SQPKTACTNCYCKKC	36
TC31	21-35	ACTNCYCKKCCFHCQ	37
TC32	26-40	YCKKCCFHCQVCFIT	38
TC33	31-45	CFHCQVCFITKALGI	39
TC34	36-50	VCFITKALGISYGRK	40
TC35	41-55	KALGISYGRKKRRQR	41
TC36	46-60	SYGRKKRRQRRRPPQ	42
TC37	51-65	KRRQRRRPPQGSQTH	43
TC38	56-70	RRPPQGSQTHQVSLS	44
TC39	61-75	GSQTHQVSLSKQPTS	45
TC40	66-80	QVSLSKQPTSQSRGD	46
TC41	71-85	KQPTSQSRGDPTGPK	47
TC42	76-90	QSRGDPTGPKEQKKK	48

[a]Peptides were designed based on HIV-1 (BH10) Tat 102 aa long.

Please amend Table 11 on page 56 to include sequence identification numbers, as follows.

Table 11. Ovalbumin peptides

Peptide ID	Ovalbumin (aa)	Peptide sequence	Class I restriction	Reference	SEQ ID NO:
CFD	11-18	CFDVFKEL	H-2K(b)	Lipford et al. J. Immunol. 1993, 150:1212-1222	50
KVV	55-62	KVVRFDKL	H-2K(b)	Mo et al. J. Immunology. 2000, 164: 4003-4010	51
SII	257-264	SIINFEKL	H-2K(b)	Catipovic et al. J. Exp. Med. 1992, 176:1611-1618	52
OVA1	25-32	ENIFYCPI	H-2K(b)	Chen et al. J Exp. Med. 1994, 180:1471-1483	53
OVA2	107-114	AEERYPIL	H-2K(b)	Lipford et al. J. Immunol. 1993, 150: 1212-1222 Chen et al. J Exp. Med. 1994, 180:1471-1483	54
OVA3	176-183	NAIVFKGL	H-2K(b)	Lipford et al. J. Immunol. 1993, 150: 1212-1222 Chen et al. J Exp. Med. 1994, 180:1471-1483	55